120 related articles for article (PubMed ID: 9390031)
1. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas.
Xerri L; Devilard E; Hassoun J; Olive D; Birg F
J Pathol; 1997 Oct; 183(2):182-7. PubMed ID: 9390031
[TBL] [Abstract][Full Text] [Related]
2. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
3. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.
Vyth-Dreese FA; Boot H; Dellemijn TA; Majoor DM; Oomen LC; Laman JD; Van Meurs M; De Weger RA; De Jong D
Immunology; 1998 Aug; 94(4):580-6. PubMed ID: 9767448
[TBL] [Abstract][Full Text] [Related]
4. Interactions of CD80 and CD86 with CD28 and CTLA4.
Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
[TBL] [Abstract][Full Text] [Related]
5. Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease.
Vandenborre K; Delabie J; Boogaerts MA; De Vos R; Lorré K; De Wolf-Peeters C; Vandenberghe P
Am J Pathol; 1998 Apr; 152(4):963-73. PubMed ID: 9546357
[TBL] [Abstract][Full Text] [Related]
6. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.
Mukherjee S; Maiti PK; Nandi D
J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713
[TBL] [Abstract][Full Text] [Related]
7. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
8. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
9. CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T-helper cell differentiation after inhaled allergen.
Burr JS; Kimzey SL; Randolph DR; Green JM
Am J Respir Cell Mol Biol; 2001 May; 24(5):563-8. PubMed ID: 11350825
[TBL] [Abstract][Full Text] [Related]
10. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.
Horspool JH; Perrin PJ; Woodcock JB; Cox JH; King CL; June CH; Harlan DM; St Louis DC; Lee KP
J Immunol; 1998 Mar; 160(6):2706-14. PubMed ID: 9510170
[TBL] [Abstract][Full Text] [Related]
11. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination.
Champagne E; Scarpellino L; Lane P; Acha-Orbea H
Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566
[TBL] [Abstract][Full Text] [Related]
12. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK
J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945
[TBL] [Abstract][Full Text] [Related]
13. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
14. T cell proliferation-augmenting activities of the gene 3 protein derived from a phage library clone with CD80-binding activity.
Fukumoto T; Torigoe N; Ito Y; Kajiwara Y; Sugimura K
J Immunol; 1998 Dec; 161(12):6622-8. PubMed ID: 9862690
[TBL] [Abstract][Full Text] [Related]
15. B70 antigen is a second ligand for CTLA-4 and CD28.
Azuma M; Ito D; Yagita H; Okumura K; Phillips JH; Lanier LL; Somoza C
Nature; 1993 Nov; 366(6450):76-9. PubMed ID: 7694153
[TBL] [Abstract][Full Text] [Related]
16. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
17. T-cell regulation by CD28 and CTLA-4.
Alegre ML; Frauwirth KA; Thompson CB
Nat Rev Immunol; 2001 Dec; 1(3):220-8. PubMed ID: 11905831
[TBL] [Abstract][Full Text] [Related]
18. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
19. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease.
Van Gool SW; Delabie J; Vandenberghe P; Coorevits L; De Wolf-Peeters C; Ceuppens JL
Leukemia; 1997 Jun; 11(6):846-51. PubMed ID: 9177439
[TBL] [Abstract][Full Text] [Related]
20. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]